Elisabeth Schwartz | Senior Director, Investor Relations |
John Thero | President and Chief Executive Officer |
Mike Kalb | Senior Vice President and Chief Financial Officer |
Yasmeen Rahimi | Roth Capital Partners |
Michael Yee | Jefferies |
Ami Fadia | SVB Leerink |
Welcome to Amarin Corporation’s Conference Call to discuss its financial and operating results for the Third Quarter of 2019.
[Operator Instructions] I would like to turn the conference call over to Elisabeth Schwartz, Senior Director of Investor Relations of Amarin.
Good morning. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor, provided by the Private Securities Litigation Reform Act.
Examples of such statements include but are not limited to are current expectations regarding our commercial and financial performance, including levels of Vascepa shipments and prescription, Vascepa’s product and licensing revenues, costs and other commercial metrics, gross margin expenditures and the adequacy of our financial resources, our current expectations regarding regulatory reviews, including our expectations related to the upcoming advisory committee meeting regarding our REDUCE-IT sNDA and our expectations for Vascepa label expansion, our current expectations for scientific presentations, publication and related timing thereof, our expectations that REDUCE-IT results could lead to a new treatment paradigm and the patient population studied, our plans and preparation for expanded promotion of Vascepa and related marketing positioning and potential, our plans to purchase additional supply of Vascepa, our goals regarding the timing and scope of international expansion and our current plans for sales force and other commercial expansion.